However, when grouping MASH patients according to the severity of histological disease activity (NAS ≤4 vs. NAS > 4) and of fibrosis (Fibrosis stage F0–1 vs. stage ≥F2), MASH patients with CKD showed an impaired postprandial GLP-2 response compared with patients without CKD (Figure 1d–e). The gene discussed is GCG; the disease is metabolic dysfunction-associated steatohepatitis.